AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 38923965
Drug: 0.01% atropine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.01% atropine administered twice daily (single vision lenses)
Trial: 38924429
Drug: AZD3152 (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD3152 (600 mg intramuscular injection)
Trial: 38924429
Drug: AZD3152 (prophylactic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD3152 (prophylactic administration)
Trial: 38924724
Drug: Atogepant 30
RxNorm normalized name: atogepant 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atogepant 30 mg BID
Trial: 38924724
Drug: Atogepant 60
RxNorm normalized name: atogepant 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atogepant 60 mg QD
Trial: 38924732
Drug: Benralizumab (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benralizumab (30 mg subcutaneous every 4 weeks)
Trial: 38924779
Drug: Normal after-visit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal after-visit summary (treatment as usual)
Trial: 38924855
Drug: Induction systemic
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction systemic therapy followed by complete local treatment
Trial: 38925354
Drug: BEP supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BEP supplementation (two 75-g sachets per day)
Trial: 38925354
Drug: BEP supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BEP supplementation + Azithromycin (20 mg/kg at 42 days)
Trial: 38925586
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg PEG-rhG-CSF
Trial: 38925586
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg PEG-rhG-CSF
Trial: 38925586
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg PEG-rhG-CSF (BW ≤ 60 kg)
Trial: 38925586
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg PEG-rhG-CSF (BW ≤ 60 kg)
Trial: 38925586
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg PEG-rhG-CSF (BW > 60 kg)
Trial: 38925586
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg PEG-rhG-CSF (BW > 60 kg)
Trial: 38925694
Drug: umbilical cord-derived
RxNorm normalized name: Allogenic umbilical cord-derived mesenchymal stem cells
DrugBank: Allogeneic umbilical cord mesenchymal stem cells (DB18367)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: umbilical cord-derived mesenchymal stem cells (UC-MSCs) treatment
Trial: 38925712
Drug: Ultrasound-guided PENG
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided PENG block with 18 mL of 0.5% ropivacaine mixed with 2 mL of a contrast agent
Trial: 38925803
Drug: Colchicine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine (0.5 mg twice daily on days 1-3, followed by 0.5 mg daily thereafter)
Trial: 38925869
Drug: High-dose allogeneic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose allogeneic disc progenitor cells
Trial: 38925869
Drug: Low-dose cells
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cells
Trial: 38926068
Drug: 27.476 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 27.476 IU YF vaccine
Trial: 38926068
Drug: 10.447 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10.447 IU YF vaccine
Trial: 38926068
Drug: 3.013 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.013 IU YF vaccine
Trial: 38926068
Drug: 587 IU
RxNorm normalized name: choline salicylate 587 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 587 IU YF vaccine
Trial: 38926068
Drug: 158 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 158 IU YF vaccine
Trial: 38926068
Drug: 31 IU
RxNorm normalized name: GLYCERETH-31
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 31 IU YF vaccine
Trial: 38926142
Drug: exergame and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: exergame and acceptance and commitment therapy (e-ACT) programme
Trial: 38926142
Drug: acceptance and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: acceptance and commitment therapy (ACT) only
Trial: 38926266
Drug: Mavacamten 15
RxNorm normalized name: mavacamten 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mavacamten 15 mg plus activated charcoal 50 g administered 2 h after mavacamten dosing
Trial: 38926266
Drug: Mavacamten 15
RxNorm normalized name: mavacamten 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mavacamten 15 mg plus activated charcoal 50 g administered 6 h after mavacamten dosing
Trial: 38926266
Drug: Mavacamten 15
RxNorm normalized name: mavacamten 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mavacamten 15 mg alone
Trial: 38926732
Drug: Ustekinumab (UST)
RxNorm normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ustekinumab (UST) treatment
Trial: 38931260
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose of DMB (150 mg DMB/tablet)
Trial: 38931260
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of DMB (300 mg DMB/tablet)
Trial: 38931260
Drug: Placebo (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (300 mg freeze-dried strawberry)
Trial: 38931864
Drug: eOD-GT8 60mer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eOD-GT8 60mer vaccine candidate
Trial: 38931864
Drug: Purified products
RxNorm normalized name: RAYON,PURIFIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Purified products from 1 L scale
Trial: 38934093
Drug: Baseline or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline or after one treatment cycle
Trial: 38934147
Drug: Ritlecitinib 200/50-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritlecitinib 200/50-mg
Trial: 38934147
Drug: Ritlecitinib 10-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritlecitinib 10-mg
Trial: 38934147
Drug: Ritlecitinib (any
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritlecitinib (any dose)
Trial: 38934231
Drug: CaHA-CMC(+) injections
RxNorm normalized name: CMC 001
DrugBank: CMC 001 (DB05353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CaHA-CMC(+) injections
Trial: 38934602
Drug: Continuous unfractionated
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous unfractionated heparin (UFH) infusion at 10 to 15 units/kg/h for infants with CRT and 2 to 3 units/kg/h without CRT
Trial: 38934602
Drug: Continuous unfractionated
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous unfractionated heparin (UFH) infusion
Trial: 38934845
Drug: mRNA-1010 (6.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRNA-1010 (6.25 µg to 200 µg)
Trial: 38934845
Drug: mRNA-1010 (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRNA-1010 (25 µg to 200 µg)
Trial: 38934845
Drug: mRNA-1010 (6.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRNA-1010 (6.25 µg to 25 µg)
Trial: 38934845
Drug: mRNA-1010 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRNA-1010 (50 µg)
Trial: 38934914
Drug: Multisession attentional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multisession attentional bias modification (ABM) training, details on dosage and duration not specified
Trial: 38934966
Drug: Hydrochlorothiazide (HCTZ)
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (HCTZ) added to intravenous furosemide regimen
Trial: 38934966
Drug: Placebo added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo added to intravenous furosemide regimen
Trial: 38934968
Drug: Evolocumab 420
RxNorm normalized name: evolocumab 420 in 3.5 ML Cartridge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evolocumab 420 mg monthly subcutaneous injections
Trial: 38935053
Drug: Nurse-led brief
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nurse-led brief behavioral treatment for insomnia (BBTI)
Trial: 38935059
Drug: Fentanyl-test (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl-test (1 mcg/kg fentanyl administration)
Trial: 38935125
Drug: Primary tumor
RxNorm normalized name: human breast tumor cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary tumor resection and systemic treatment (PTR+SYST)
Trial: 38935125
Drug: Systemic treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Systemic treatment only (SYST)
Trial: 38936466
Drug: Fluticasone furoate/vilanterol
RxNorm normalized name: fluticasone furoate/vilanterol 100/25 MCG/INHAL Dry Powder Inhaler, 30 Blisters
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone furoate/vilanterol (FF/VI) 50/25 µg once daily
Trial: 38936466
Drug: Fluticasone furoate
RxNorm normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluticasone furoate (FF) 50 µg once daily
Trial: 38936755
Drug: Low-dose colchicine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose colchicine 0.5 mg daily
Trial: 38937182
Drug: Four-dose test
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four-dose test group (2-1-1 regimen)
Trial: 38937182
Drug: Four-dose control
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four-dose control group
Trial: 38937182
Drug: Five-dose control
RxNorm normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five-dose control group
Trial: 38937182
Drug: Four-dose test
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four-dose test group
Trial: 38937310
Drug: Early palliative
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early palliative care (EPC) integration, monthly meetings with a palliative care team for 12 months
Trial: 38937404
Drug: Certolizumab pegol
RxNorm normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Certolizumab pegol (CZP) 400 mg initial doses at weeks 0, 2, and 4, followed by CZP 200 mg every 2 weeks or CZP 400 mg every 2 weeks maintenance dosing.
Trial: 38937792
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment of surgeon's choice
Trial: 38937798
Drug: Personalized Citizen
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Personalized Citizen Assistance for Social Participation (APIC); weekly 3-h personalized stimulation sessions given by a trained volunteer over a 12-month period
Trial: 38937803
Drug: Haploidentical CD34+
RxNorm normalized name: Autologous CD34+ cells encoding βA-T87Q-Globin gene
DrugBank: Betibeglogene autotemcel (DB16900)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haploidentical CD34+ enriched and CD45RA-depleted hematopoietic progenitor cell grafts followed by NK-cell infusion
Trial: 38937824
Drug: Virtual reality
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual reality cue-exposure therapy (VRCET) plus memory-focused cognitive therapy (MFCT)
Trial: 38937824
Drug: Picture-based cue-exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Picture-based cue-exposure therapy (PCET)
Trial: 38938387
Drug: Self-administered SAGE
RxNorm normalized name: SAGE
DrugBank: Sage (DB10982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administered SAGE used during PCP visits
Trial: 38939480
Drug: Recommended dose
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recommended dose edoxaban
Trial: 38939629
Drug: Organized treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Organized treatment pathway
Trial: 38939828
Drug: Raloxifene 60
RxNorm normalized name: raloxifene 60 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene 60 mg/day plus cholecalciferol 800 IU/day (RalD)
Trial: 38940282
Drug: Apalutamide 240
RxNorm normalized name: apalutamide 240 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apalutamide 240 mg/day
Trial: 38940373
Drug: Oregovomab plus
RxNorm normalized name: Oregovomab
DrugBank: Oregovomab (DB04964)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oregovomab plus non-platinum-based chemotherapy (pegylated liposomal doxorubicin or paclitaxel)
Trial: 38940373
Drug: Non-platinum-based chemotherapy
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-platinum-based chemotherapy (pegylated liposomal doxorubicin or paclitaxel)
Trial: 38940733
Drug: Photobiomodulation Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photobiomodulation Treatment with a Home-Use Device
Trial: 38940981
Drug: Ovarian function
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ovarian function recovery (OFR) in patients with CIOFF receiving anastrozole treatment.
Trial: 38941062
Drug: Metal-on-polyethylene (MoP)
RxNorm normalized name: polyethylenes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metal-on-polyethylene (MoP) arthroplasty implants
Trial: 38941062
Drug: MoP arthroplasty
RxNorm normalized name: methoxsalen
DrugBank: Methoxsalen (DB00553)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MoP arthroplasty implants
Trial: 38941132
Drug: Concurrent validity
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent validity of 6MST compared to CPET and 6MWT
Trial: 38941376
Drug: Raftlin level
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raftlin level ≥ 6.31 ng/mL
Trial: 38941599
Drug: Syalox 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Syalox 300 Plus (high-molecular-weight hyaluronic acid) administered orally for 8 weeks.
Trial: 38942047
Drug: Namilumab 150
RxNorm normalized name: sarilumab
DrugBank: Sarilumab (DB11767)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Namilumab 150 mg subcutaneously at weeks 0, 2, 6, and 10
Trial: 38942114
Drug: Elevated Lp(a)
RxNorm normalized name: LP-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elevated Lp(a) (≥150 nmol/L)
Trial: 38942591
Drug: MIST discontinuation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MIST discontinuation group (n=27)
Trial: 38942592
Drug: Nipocalimab (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nipocalimab (15 mg/kg intravenously every 2 weeks)
Trial: 38942693
Drug: Vicriviroc 150
RxNorm normalized name: Vicriviroc
DrugBank: Vicriviroc (DB06652)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vicriviroc 150 mg orally once daily plus pembrolizumab 200 mg intravenously every 3 weeks
Trial: 38942693
Drug: Vicriviroc 250
RxNorm normalized name: Vicriviroc
DrugBank: Vicriviroc (DB06652)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vicriviroc 250 mg orally once daily plus pembrolizumab 200 mg intravenously every 3 weeks
Trial: 38942994
Drug: AAV gene
RxNorm normalized name: Immature cell growth-inhibiting gene 1 protein
DrugBank: Cerliponase alfa (DB13173)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: AAV gene therapy (AP4M1 gene) administered intrathecally
Trial: 38943053
Drug: Educational program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Educational program combining three nutritional workshops and 12 weekly physical activity sessions.
Trial: 38943063
Drug: Qualitative evaluation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qualitative evaluation of treatment suitability for CEBA profiles in a small group of PwMS.
Trial: 38943192
Drug: Vilobelimab (C5a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vilobelimab (C5a inhibitor)
Trial: 38943294
Drug: Short messages
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short messages informing relatives during surgery (preparations for surgery have begun, surgery has started, surgery is ongoing, surgery is completed)
Trial: 38943664
Drug: Sapanisertib (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sapanisertib (5 mg daily)
Trial: 38943928
Drug: Luvadaxistat 50
RxNorm normalized name: Luvadaxistat
DrugBank: Luvadaxistat (DB16067)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Luvadaxistat 50 mg
Trial: 38943928
Drug: Luvadaxistat 125
RxNorm normalized name: Luvadaxistat
DrugBank: Luvadaxistat (DB16067)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Luvadaxistat 125 mg
Trial: 38943928
Drug: Luvadaxistat 500
RxNorm normalized name: Luvadaxistat
DrugBank: Luvadaxistat (DB16067)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Luvadaxistat 500 mg
Trial: 38944045
Drug: Natural cycle
RxNorm normalized name: Natural Cycles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natural cycle endometrial preparation
Trial: 38944045
Drug: Modified natural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified natural cycle endometrial preparation
Trial: 38944045
Drug: Artificial cycle
RxNorm normalized name: COLOR,ARTIFICIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artificial cycle endometrial preparation
Trial: 38944806
Drug: Stereotactic body
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stereotactic body radiation therapy (SBRT) and androgen deprivation therapy (ADT) for at least 24 months
Trial: 38945140
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment targeting systolic blood pressure of less than 120 mm Hg
Trial: 38945140
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment targeting systolic blood pressure of less than 140 mm Hg
Trial: 38945800
Drug: Furmonertinib combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furmonertinib combined with carboplatin and pemetrexed for 4 cycles, then furmonertinib and pemetrexed as maintenance therapy (Arm B2)
Trial: 38945800
Drug: Furmonertinib combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furmonertinib combined with carboplatin and pemetrexed for 4 cycles, then furmonertinib and pemetrexed as maintenance therapy plus bevacizumab (Arm B3)
Trial: 38945800
Drug: Furmonertinib monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furmonertinib monotherapy (Arm B1)
Trial: 38946384
Drug: Mini-fluid challenge
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mini-fluid challenge (MFC) with 100 mL of crystalloids
Trial: 38946484
Drug: ABBV-184 (0.07
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABBV-184 (0.07 ug/kg initially, with 2- to 3-fold dose increases)
Trial: 38946973
Drug: JAK inhibitor
RxNorm normalized name: Janus-associated kinase (JAK) inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JAK inhibitor tofacitinib
Trial: 38947093
Drug: Xpert HR-CAD4TB
RxNorm normalized name: CPERT
DrugBank: Technetium Tc-99m pertechnetate (DB09314)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xpert HR-CAD4TB (sequential negative screening)
Trial: 38947093
Drug: CRP-CAD4TB (sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRP-CAD4TB (sequential negative screening)
Trial: 38947093
Drug: Xpert HR-CAD4TB
RxNorm normalized name: CPERT
DrugBank: Technetium Tc-99m pertechnetate (DB09314)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xpert HR-CAD4TB (sequential positive screening)
Trial: 38947228
Drug: CPX-351 (liposomal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPX-351 (liposomal daunorubicin and cytarabine) administered at 135 units/m
Trial: 38948487
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment plus exercise therapy
Trial: 38948487
Drug: Sham acupuncture
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham acupuncture plus exercise therapy
Trial: 38949715
Drug: Complete decongestive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complete decongestive therapy (CDT) 5 days a week for 3 weeks in MetS group
Trial: 38949715
Drug: Complete decongestive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complete decongestive therapy (CDT) 5 days a week for 3 weeks in control group
Trial: 38949758
Drug: Vupanorsen 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vupanorsen 80 mg
Trial: 38949758
Drug: Vupanorsen 160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vupanorsen 160 mg
Trial: 38949813
Drug: Clinician nudge
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinician nudge only (active control + weekly peer comparisons)
Trial: 38950321
Drug: Two cycles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two cycles of induction immunochemotherapy followed by SCRT and the rest four doses (Group B)